Clinical Trial Update: A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing BGB-16673 to investigator's choice in chronic lymphocytic leukemia or small lymphocytic lymphoma patients who have previously…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• BGB-16673

Snippet

Sponsor: BeOne Medicines | Conditions: CLL, Chronic Lymphocytic Leukemia | Phase 3 | Status: RECRUITING